Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cutaneous Medicine and Surgery
Published in: Journal of Cutaneous Medicine and Surgery 5/2004

01-10-2004

Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel

Authors: Lyn Guenther, Richard G. Langley, Neil H. Shear, Robert Bissonnette, Vincent Ho, Charles Lynde, Eileen Murray, Kim Papp, Yves Poulin, Catherine Zip

Published in: Journal of Cutaneous Medicine and Surgery | Issue 5/2004

Login to get access

Abstract

Background

Approximately 2% of people worldwide have psoriasis, with as many as 1 million people with psoriasis in Canada alone.1,2 The severity of psoriasis ranges from mild to severe. It can lead to substantial morbidity and psychological stress and have a profound negative impact on patient quality of life.3,4 Although available therapies reduce therapies reduce the extent and severity of the disease and improve quality of life,3 reports have indicated a patient preference for more aggressive therapy and a dissatisfaction with the effectiveness of current treatment options.5

Objective

A Canadian Expert Panel, comprising Canadian dermatologists, convened in Toronto on 27 February 2004 to reach a consensus on unmet needs of patients treated with current therapies and how to include the pending biologic agents in and improve the current treatment algorithm for moderate-to-severe psoriasis. Current treatment recommendations suggest a stepwise strategy starting with topical agents followed by phototherapy and then systemic agents.3,6,7 The Panel evaluated the appropriate positioning of the biologic agents, once approved by Health Canada, for the treatment of moderate-to-severe psoriasis.

Methods

The Panel reviewed available evidence and quality of these data on current therapies and from randomized, controlled clinical trials.8‐14 Subsequently, consensus was achieved by small-group workshops followed by plenary discussion.

Results

The Panel determined that biologic agents are an important addition to therapies currently available for moderate-to-severe psoriasis and proposed an alternative treatment algorithm to the current step wise paradigm.

Conclusion

The Panel recommended a new treatment algorithm for moderate-to-severe psoriasis whereby all appropriate treatment options, including biologic agents, are considered together and patients’ specific characteristics and needs are taken into account when selecting the most appropriate treatment option.
Literature
1.
2.
Nail, L, Gulliver, W, Charmley, P,  et al. 1999Search for the psoriasis susceptibility gene: the Newfoundland StudyCutis 64323329
3.
Ashcroft, DM, Li Wan Po, A, Griffiths, CE 2000Therapeutic strategies for psoriasisJ Clin Pharm Ther25110CrossRefPubMed
4.
5.
Krueger, G, Koo, J, Lebwohl, M,  et al. 2001The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol137280284PubMed
6.
7.
Travis, L, Weinberg, JM 2002Medical backgrounder: psoriasisDrugs Today (Barc)38847865CrossRef
8.
Leonardi, CL, Powers, JL, Matheson, RT,  et al. 2003Etanercept as monotherapy in patients with psoriasisN Engl J Med34920142022CrossRefPubMed
9.
Krueger, GG, Papp, KA, Stough, DB,  et al. 2002A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol47821833CrossRefPubMed
10.
Gottlieb, AB, Chaudhari, U, Mulcahy, LD,  et al. 2003Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasisJ Am Acad Dermatol48829835CrossRefPubMed
11.
Chaudhari, U, Romano, P, Mulcahy, LD,  et al. 2001Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialLancet35718421847CrossRefPubMed
12.
Lebwohl, M, Tyring, SK, Hamilton, TK,  et al. 2003A novel targeted T-cell modulator, efalizumab, for plaque psoriasisN Engl J Med34920042013CrossRefPubMed
13.
Gordon, KB, Papp, KA, Hamilton, TK,  et al. 2003Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialJAMA29030733080PubMed
14.
Ortonne, JP 2003Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasisJ Eur Acad Dermatol Venereol171216CrossRefPubMed
15.
16.
Brandrup, F, Green, A 1981The prevalence of psoriasis in DenmarkActa Derm Venereol61344346PubMed
17.
Henseler, T, Christophers, E 1985Psoriasis of early and late onset: characterization of two types of psoriasis vulgarisJ Am Acad Dermatol13450456PubMedCrossRef
18.
Whittam, LR, McGibbon, DH 1998The management of psoriasisInt J Clin Pract52487491PubMed
19.
Callen, JP, Krueger, GG, Lebwohl, M,  et al. 2003AAD consensus statement on psoriasis therapiesJ Am Acad Dermatol49897899CrossRefPubMed
20.
Krueger, GG, Feldman, SR, Camisa, C,  et al. 2000Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?J Am Acad Dermatol43281285CrossRefPubMed
21.
Feldman, SR 2004A quantitative definition of severe psoriasis for use in clinical trialsJ Dermatolog Treat152729CrossRefPubMed
22.
23.
Lebwohl, M, Ali, S 2001Treatment of psoriasis. Part 1 . Topical therapy and phototherapyJ Am Acad Dermatol45487498quiz 499–502CrossRefPubMed
24.
Lebwohl, M, Ali, S 2001Treatment of psoriasis. Part 2. Systemic therapiesJ Am Acad Dermatol45649661quiz 662–664PubMed
25.
Gower, WR,Jr 1993Mechanism of glucocorticoid actionJ Fla Med Assoc80697700PubMed
26.
Foster, RH, Broaden, RN, Benfield, P 1998TazaroteneDrugs55705711discussion 712PubMed
27.
Muller, K 2000Current status and recent developments in anthracenone antipsoriaticsCurr Pharm Des6901918CrossRefPubMed
28.
Pardasani, AG, Feldman, SR, Clark, AR 2000Treatment of psoriasis: an algorithm-based approach for primary care physiciansAm Fam Physician61725733, 736PubMed
29.
Camisa C, ed. UVB phototherapy and coal tar. In: Chapter 12, Camisa, C (ed.), Psoriasis, Boston, Blackwell Scientific, 1994, pp 205–226
30.
Gawkrodger, D on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists1997Current management of psoriasisJ Dermatology Treat82755CrossRef
31.
Krutmann, J 1998Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapyJ Photochem Photobiol B44159164CrossRefPubMed
32.
Melski, JW, Tanenbaum, L, Parrish, JA,  et al. 1977Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trialJ Invest Dermatol68328335CrossRefPubMed
33.
Griffiths, CE, Clark, CM, Chalmers, RJ,  et al. 2000A systematic review of treatments for severe psoriasisHealth Technol Assess41125PubMed
34.
Gordon, PM, Diffey, BL, Matthews, JN,  et al. 1999A randomized comparison of narrowband TL-01 phototherapy and PUVA photochemotherapy for psoriasisJ Am Acad Dermatol41728732PubMed
35.
36.
37.
Ramsay, CA, Schwartz, BE, Lowson, D,  et al. 2000Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study GroupDermatology2001724CrossRefPubMed
38.
Margolis, D, Bilker, W, Hennessy, S,  et al. 2001The risk of malignancy associated with psoriasisArch Dermatol137778789PubMed
39.
Compendium of pharmaceuticals and specialties. Ed. Ottawa: Canadian Pharmacists’ Associatin, 2004
40.
Roenigk, HH,Jr, Auerbach, R, Maibach, H,  et al. 1998Methotrexate in psoriasis: consensus conferenceJ Am Acad Dermatol38478485PubMed
41.
Heydendael, VM, Spuls, PI, Opmeer, BC,  et al. 2003Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasisN Engl J Med349658665CrossRefPubMed
42.
Callis KP, Chadha A, Vaishnaw AK, et al. Reduction of CD45RP+ Effector T lymphocytes is not observed in the treatment of psoriasis with methotrexate. Presented at 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, CA, poster abstract 220. May 15–18, 2002
43.
Ho, VC, Griffiths, CE, Berth–Jones, J,  et al. 2001Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort studyJ Am Acad Dermatol44643651PubMed
44.
Shupack, J, Abel, E, Bauer, E,  et al. 1997Cyclosporine as maintenance therapy in patients with severe psoriasisJ Am Acad Dermatol36423432PubMed
45.
Roenigk, HH,Jr 1999Acitretih combination therapyJ Am Acad Dermatol41S18S21PubMed
46.
Lebwohl, M, Christophers, E, Langley, R,  et al. 2003An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol139719727CrossRefPubMed
47.
Linden, KG, Weinstein, GD 1999Psoriasis: current perspectives with an emphasis on treatmentAm J Med107595605CrossRefPubMed
48.
Koo, J, Lebwohl, M 1999Duration of remission of psoriasis therapiesJ Am Acad Dermatol415159PubMed
49.
Boerbooms, AM, Kerstens, PJ, Loenhout, JW,  et al. 1995Infections during low-dose methotrexate treatment in rheumatoid arthritisSemin Arthritis Rheum24411421CrossRefPubMed
50.
Lebwohl, M, Menter, A, Koo, J,  et al. 2004Combination therapy to treat moderate to severe psoriasisJ Am Acad Dermatol50416430PubMed
51.
Weinstein, GD, White, GM 1993An approach to the treatment of moderate to severe psoriasis with rotational therapyJ Am Acad Dermatol28454459PubMed
52.
Koo, J 1999Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic resultsJ Am Acad Dermatol41S25S28PubMed
53.
54.
Rapp, SR, Feldman, SR, Exum, ML,  et al. 1999Psoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol41401407PubMed
55.
Naldi, L, Svensson, A, Diepgen, T,  et al. 2003Randomized clinical trials for psoriasis 1977–2000: the EDEN surveyJ Invest Dermatol120738741CrossRefPubMed
56.
Krueger, JG 2002The immunologic basis for the treatment of psoriasis with new biologic agentsJ Am Acad Dermatol46123quiz 26PubMed
57.
Gordon K, Pariser D, Langley R, et al. Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials. Presented at 62nd Annual Meeting of the American Acadamy of Dermatology, 6–11 February 2004, Washington, DC, poster 4
58.
Leonardi CI, Goffe B, Sobell J, et al. The safety of efalizumab in patients with moderate to severe plaque psoriasis: Summary of clinical trial experience. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 613
59.
Remicade® (infliximab), US prescribing information, 2003. Manufactured by Centocor, Inc.
60.
61.
62.
63.
Cather, JC, Abramovits, W 2003Investigational therapies for psoriasisJ Am Acad Dermatol49S133S138CrossRefPubMed
64.
Singri, P, West, DP, Gordon, KB 2002Biologic therapy for psoriasis: the new therapeutic frontierArch Dermatol138657663CrossRefPubMed
65.
Gordon, KB, McCormick, TS 2003Evolution of biologic therapies for the treatment of psoriasisSkinmed2286294PubMed
66.
Gottlieb AB, Evans R, Li S, et al. The efficacy of infliximab across a variety of subgroups with plaque psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 615
67.
Gordon, KB, Vaishnaw, AK, O’Gorman, J,  et al. 2003Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsArch Dermatol13915631570CrossRefPubMed
68.
Menter A, Gather JC. Long-term use of intravenous alefacept: Safety and off-treatment responses in patients who have received four or more courses of therapy. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 588
69.
Ellis, CN, Mordin, MM, Adler, EY 2003Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trialAm J Clin Dermatol4131139PubMed
70.
Gottlieb AB, Gordon KB, Caro I, et al. Long-term efalizumab therapy safely maintains psoriasis area and severity index improvement: Preliminary results from an open-label trial. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 611
71.
Menter A, Toth D, Glazer S, et al. Efficacy and safety of 24-week continuous efalizumab therapy in patients with moderate to severe plaque psoriasis. Presented at Summer Academy 2003 of the American Academy of Dermatology, 25–29 July 2003, Chicago, IL, poster 44
72.
Menter A, Hamilton T, Caro I, et al. Impact of efalizumab on patient-reported outcomes in patients with chronic moderate to severe plaque psoriasis: pooled results from three randomized phase III trials. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 608
73.
Stone S, Papp KA, Caro I, et al. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 610
74.
Leonardi CL, Elewski B, Camisa C, et al. The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 568
75.
Krueger GG, Lebwohl M, Wang A, et al. Continuance on etanercept after early incomplete response in patients with psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 546
76.
Elewski BE, Boh E, Papp K, et al. Efficacy and safety of etanercept in patients with psoriasis: Results of a global phase III study. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 618
77.
Ogilvie A, Antoni C, Kavanaugh A, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): Substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Presented at 96th International Psoriasis Symposium, 18–22 June 2003, New York, NY, poster 8
78.
Feldman SR, Bala M, Menter A, et al. The quality of life of patients with severe psoriasis treated with infliximab. Presented at 62nd Annual Meeting of the American Academy of Dermatology, February 6–11 2004, Washington, DC, poster 7
79.
Guidelines of care for psoriasis. Committee on Guidelines of Care.1993Task Force on PsoriasisJ Am Acad Dermatol28632637CrossRef
80.
Lebwohl, M 2003Combining the new biologic agents with our current psoriasis armamentariumJ Am Acad Dermatol49S118S124CrossRefPubMed
81.
Kostovic, K, Nola, I 2002Phototherapy (UVB) and photochemotherapy (PUVA) for psoriasisActa Clin Croat41103112
82.
8-Mop®capsules (methoxsalen capsules, USP, 10 mg), US prescribing information, 2003 ICN Pharmaceutical Inc.
83.
Brown, SL, Greene, MH, Gershon, SK,  et al. 2002Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug AdministrationArthritis Rheum4631513158PubMed
84.
The Lenercept Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group.1999TNF neutralization in MS: results of a randomized placebo-controlled multicenter studyNeurology53457465
85.
Klareskog, L, Heijde, D, Jager, JP,  et al. 2004Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet363675681CrossRefPubMed
Metadata
Title
Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel
Authors
Lyn Guenther
Richard G. Langley
Neil H. Shear
Robert Bissonnette
Vincent Ho
Charles Lynde
Eileen Murray
Kim Papp
Yves Poulin
Catherine Zip
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Journal of Cutaneous Medicine and Surgery / Issue 5/2004
Print ISSN: 1203-4754
Electronic ISSN: 1615-7109
DOI
https://doi.org/10.1007/s10227-005-0035-1

Other articles of this Issue 5/2004

Journal of Cutaneous Medicine and Surgery 5/2004 Go to the issue

OriginalPaper

12-Cancer

OriginalPaper

13. Wound Healing

OriginalPaper

1.-Medical Practice

OriginalPaper

5.–HIV and Infectious Diseases

OriginalPaper

10.-Inflammatory Dermatoses

OriginalPaper

8.-Pathology